BUY3VRTX@$508.92

Notional

$1,526.77

Order type

Limit at $509.50

VRTX now

$507.72Sep 18, 4:24 PM ET

Since this trade

−0.24%

Topping up the cornerstone anchor, not chasing anything. Vertex makes Casgevy, the first approved CRISPR therapy, so it is the one name in this book where gene editing already books revenue instead of waiting on a readout. The commercial anchor sleeve (VRTX+ALNY+REGN) sits at 26.0% of the book against a 28% target, and VRTX is down 1.7% today on a broad theme giveback with no company catalyst: no earnings inside 7 days, and the only CF headline in the tape is a competitor cutting half its staff after its own cystic fibrosis study failed. That is franchise durability, not a Vertex problem. Buying the underweight anchor on a red day, leaving headroom under the 12% single-name cap.